Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H21N3 |
| Molecular Weight | 291.3901 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1CCN(CC1)C2=NC3=CC=CC=C3CC4=CC=CC=C24
InChI
InChIKey=PWRPUAKXMQAFCJ-UHFFFAOYSA-N
InChI=1S/C19H21N3/c1-21-10-12-22(13-11-21)19-17-8-4-2-6-15(17)14-16-7-3-5-9-18(16)20-19/h2-9H,10-14H2,1H3
| Molecular Formula | C19H21N3 |
| Molecular Weight | 291.3901 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: http://www.ncbi.nlm.nih.gov/pubmed/9577836Curator's Comment: Description is created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/4359662 and http://www.ncbi.nlm.nih.gov/pubmed/4695567
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836
Curator's Comment: Description is created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/4359662 and http://www.ncbi.nlm.nih.gov/pubmed/4695567
Perlapine is a sedative and hypnotic drug.The drug brand named Hypnodin contains generic salt-Perlapine and is manufactured by Takeda Pharmaceutical. Perlapine is a potent H1R inverse agonist. It showed robust sedative effects clinically. Perlapine belongs to antipsychotic drugs which elicit little or no Parkinsonism, it binds more loosely than dopamine to D2 receptors.
CNS Activity
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL339 Sources: http://www.ncbi.nlm.nih.gov/pubmed/11462978 |
2.7 µM [IC50] | ||
Target ID: CHEMBL231 Sources: http://www.ncbi.nlm.nih.gov/pubmed/17403993 |
9.7 null [pIC50] | ||
Target ID: CHEMBL217 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836 |
60.0 nM [Kd] | ||
Target ID: CHEMBL234 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836 |
100.0 nM [Kd] | ||
Target ID: CHEMBL219 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836 |
30.0 nM [Kd] | ||
Target ID: CHEMBL224 Sources: http://www.ncbi.nlm.nih.gov/pubmed/9577836 |
13.0 nM [Kd] | ||
Target ID: CHEMBL1945 Sources: http://www.genome.jp/dbget-bin/www_bget?D01438 |
|||
Target ID: CHEMBL1946 Sources: http://www.genome.jp/dbget-bin/www_bget?D01438 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Hypnodin Approved UseHypnotic and sedative |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Perlapine: relationship between stimulation of prolactin secretion and antipsychotic activity. | 1977-10-20 |
|
| Perlapine and dopamine metabolism: prediction of antipsychotic efficacy. | 1977-01-07 |
|
| Anti-dopaminergic and anti-muscarinic effects of dibenzodiazepines: relationship to drug induced Parkinsonism. | 1976 |
|
| Effects of clozapine, thioridazine, perlapine and haloperidol on the metabolism of the biogenic amines in the brain of the rat. | 1975 |
|
| The effects of perlapine on sleep. | 1973-08-22 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/4359662
10 - 20 mg of perlapine nightly to improve sleep
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/11462978
Perlapine inhibited spiropiperidone binding at dopamine receptor D2 of rat with IC50 2.7uM
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:33:55 GMT 2025
by
admin
on
Mon Mar 31 17:33:55 GMT 2025
|
| Record UNII |
4N8UJJ27IM
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C29756
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
2825
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
291840
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
100000082222
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
2111
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
C80676
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
Perlapine
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
16106
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
CHEMBL340801
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
DTXSID1048758
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
C003910
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
SUB09733MIG
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
1977-11-3
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | |||
|
m8563
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY | Merck Index | ||
|
4N8UJJ27IM
Created by
admin on Mon Mar 31 17:33:55 GMT 2025 , Edited by admin on Mon Mar 31 17:33:55 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |